Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunvozertinib adjuvant therapy after complete resection for EGFR exon 20 insertion-mutant NSCLC
ChiCTR2400094167Phase 2Recruiting
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunvozertinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: 3-year disease-free survival rate. Started Dec 2024; status: recruiting.
02
Drugs
sunvozertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400094167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094167.